FDA voices concerns over cataracts in children taking Kalydeco
This article was originally published in Scrip
Executive Summary
The US FDA is warning the cystic fibrosis (CF) community about a potential safety concern of cataract development in children with CF taking Vertex Pharmaceuticals' Kalydeco (ivacaftor). The warning stems from recent results from a study in juvenile rats that was conducted to support the treatment of young children less than two years of age with Kalydeco.